Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis - Top-Institutions - MDSpire

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

  • By

  • Rodrigo R. de Sena

  • Kleyton de C Mesquita

  • Letícia F. Barroso

  • Paola B. E. Canabrava

  • Fernando Zanghelini

  • Ciro M. Gomes

  • March 18, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Pharmacology

  • #2

    National Psoriasis Foundation Research Center at Oregon Health & Science University (OHSU)
    National Psoriasis Foundation Research Center at Oregon Health & Science University (OHSU)

    Portland, OR

    Key Differentiators

    • Dermatology
    • Immunology
    • Psoriasis Research

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #5

    King's College London, Dermatology Department
    King's College London, Dermatology Department

    London, N/A

    Key Differentiators

    • Dermatology
    • Immunology
    • Psoriasis Research

Original Source(s)

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

  • by Rodrigo R. de Sena, Kleyton de C Mesquita, Letícia F. Barroso, Paola B. E. Canabrava, Fernando Zanghelini, Ciro M. Gomes

  • March 18, 2026

Related Content

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)